Xu Dixon H, Zhu Ziwen, Xiao Huaping, Wakefield Mark R, Bai Qian, Nicholl Michael B, Ding Vivi A, Fang Yujiang
Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA 50312, USA.
Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, USA.
Cancer Lett. 2017 May 28;394:43-51. doi: 10.1016/j.canlet.2017.02.022. Epub 2017 Feb 28.
Melanoma is the leading cause of death among all skin cancers and its incidence continues to rise rapidly worldwide in the past decades. The available treatment options for melanoma remain limited despite extensive clinical research. Melanoma is an immunogenic tumor and great advances in immunology in recent decades allow for the development of immunotherapeutic agents against melanoma. In recent years, immunotherapy utilizing cytokines has been particularly successful in certain cancers and holds promise for patients with advanced melanoma. In this review, an overview of the current status and emerging perspectives on cytokine immunotherapy for melanoma are discussed in details. Such a study will be helpful to unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
黑色素瘤是所有皮肤癌中导致死亡的主要原因，在过去几十年里，其发病率在全球范围内持续迅速上升。尽管进行了广泛的临床研究，但黑色素瘤可用的治疗选择仍然有限。黑色素瘤是一种免疫原性肿瘤，近几十年来免疫学的巨大进展使得针对黑色素瘤的免疫治疗药物得以开发。近年来，利用细胞因子的免疫疗法在某些癌症中特别成功，为晚期黑色素瘤患者带来了希望。在这篇综述中，将详细讨论黑色素瘤细胞因子免疫治疗的现状和新观点。这样的研究将有助于揭开基于细胞因子的黑色素瘤免疫治疗的神秘面纱。
